Patents Examined by Michael J Schmitt
  • Method for predicting a treatment response to a CRHR1 antagonist and/or a Vantagonist in a patient with depressive and/or anxiety symptoms
    Patent number: 10837062
    Abstract: A method of treating a human patient with depressive and/or anxiety symptoms which includes administering an effective amount of a V1B receptor antagonist and/or CRHR1 antagonist to the patient in need thereof, wherein the patient's genome has certain polymorphoric variants.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: November 17, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Florian Holsboer, Bertram Müller-Myhsok
  • Pre-frontal cortex processing disorder speech gait and limb impairments treatment
    Patent number: 10834891
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: November 17, 2020
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Fatty acids as anti-inflammatory agents
    Patent number: 10835518
    Abstract: Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, Ra, Rb, Rb?, Rc, and Rc? are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: November 17, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Methods and materials for treating estrogen receptor positive breast cancer
    Patent number: 10815534
    Abstract: This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A?G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 27, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Tanda T. Dudenkov, Liewei Wang, James N. Ingle, Richard M. Weinshilboum, Junmei Cairns
  • Methods of treating cancer with farnesyltransferase inhibitors
    Patent number: 10806730
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject having clinical signs of bone marrow homing of myeloid cells, including neutropenia, isolated neutropenia, a low percentage of peripheral blood blasts with or without a high percentage of bone marrow blasts, and/or a low ratio of peripheral blood blasts to bone marrow blasts, with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on hematological characteristics indicating bone marrow homing of myeloid cells.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: October 20, 2020
    Assignee: Kura Oncology, Inc.
    Inventor: Antonio Gualberto
  • Medicinal composition for treating urinary tract infection (UTI)
    Patent number: 10772901
    Abstract: Provided is a pharmaceutical composition for use in a method of preventing or treating a urinary tract infection (UTI), chronic cystitis, overactive bladder, partial bladder obstruction or urethritis, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, where in said method said composition is administered intraurethrally, intravesically, intraureterally and/or intrarenally, as well as a pharmaceutical composition for use in a method of preventing or treating bladder cancer, where in said method said composition is administered intravesically, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, wherein said tannins are bound to an anti-cancer agent and/or liposomes containing an anti-cancer agent, together with compositions related thereto.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 15, 2020
    Assignees: UroPharma Limited, Synesis LLC
    Inventors: Howard Shapland, Scott Glickman, Christian G. Krueger, Amy B. Howell, Jess D. Reed
  • Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
    Patent number: 10765665
    Abstract: A formulation, especially one that is topically administered, comprising a combination of rapamcycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. The topical formulation may be a gel, an ointment, a cream or a lotion. The topical formulation may be used to treat any disease associated with inflammation and/or any inflammatory skin disease.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: September 8, 2020
    Inventor: Jeffrey Melin
  • Methods for treating irritable bowel syndrome (IBS)
    Patent number: 10765667
    Abstract: The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: September 8, 2020
    Assignee: Salix Pharmaceuticals, Inc.
    Inventors: William Forbes, Enoch Bortey
  • Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto
    Patent number: 10759803
    Abstract: This disclosure relates to asparagine endopeptidase inhibitors for managing cancer and compositions related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are substituted 3,7-dihydropurine-2,6-dione derivatives useful for treating or preventing metastasis, tumor growth, and/or cancer. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising an asparagine endopeptidase inhibitor and a pharmaceutically acceptable excipient. In certain embodiments, the disclosure relates to methods of treating a cancer comprising administering an effective amount of pharmaceutical composition a asparagine endopeptidase inhibitor disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: September 1, 2020
    Assignee: Emory University
    Inventors: Keqiang Ye, Haian Fu, Yuhong Du
  • Choroidal neovascularization suppressor or drusen formation suppressor, and method for assessing or screening for same
    Patent number: 10761087
    Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 1, 2020
    Assignees: LINK GENOMICS, INC., ROHTO Pharmaceutical Co., Ltd.
    Inventors: Shinichiro Niwa, Dai Ogura, Hidemi Mizunuma, Yoko Arai, Takahiro Kurose, Yoshihiro Takai, Yoko Mitsuguchi, Mariyo Moriya
  • Compounds as L-cystine crystallization inhibitors and uses thereof
    Patent number: 10759748
    Abstract: A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: R1a—[O]v-(-A-L-)m-A-[O]v—R1b?? I wherein A, L, R1a, R1b, m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: September 1, 2020
    Assignee: New York University
    Inventors: Michael D. Ward, Zina Zhu
  • GLS1 inhibitors for treating disease
    Patent number: 10738043
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: August 11, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
  • Method of treating dyskinesia
    Patent number: 10736889
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a ?-opioid receptor antagonist or prodrug thereof, and a ?-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 11, 2020
    Assignee: Rutgers, The State University of New Jersey
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Quaternary fungicidal mixture
    Patent number: 10729137
    Abstract: A quaternary fungicide mixture for controlling diseases of turfgrass and/or ornamentals.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: August 4, 2020
    Assignee: ADAMA MAKHTESHIM LTD.
    Inventors: Allan S. Las, Jerry L. Corbett, Paul R. Moore
  • Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
    Patent number: 10729664
    Abstract: The invention provides compounds, compositions, methods, and kits for the treatment of neurogenic inflammation.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: August 4, 2020
    Assignees: President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Clifford J. Woolf, Bruce P. Bean
  • Treprostinil administration by inhalation
    Patent number: 10716793
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: July 21, 2020
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Methods of reducing risk of cardiovascular disease
    Patent number: 10709678
    Abstract: Methods of lowering the plasma LDL-C levels in a patient on a stable dose of statin where the patient has an LDL-C level above treatment goal. Methods of decreasing a patient's risk for developing coronary heart disease, having a recurrent cardiovascular event or reducing the severity of a secondary cardiovascular event, wherein the patient is on a stable dose of statin and the patient has an LDL-C level above treatment goal.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: July 14, 2020
    Assignee: NeuroBo Pharmaceuticals, Inc.
    Inventor: Charles L. Bisgaier
  • 2,4-pyrimidinediamine compounds and their uses
    Patent number: 10709703
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: July 14, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
  • Reagent and kit for performing chemiluminescent reaction
    Patent number: 10711185
    Abstract: A reagent for performing a chemiluminescent reaction includes luminol or luminol derivatives, an oxidant, an electron mediator, and an enhancer. The enhancer is a nitrogen-containing fused heterocyclic compound having at least two nitrogen atoms. The present disclosure further provides a kit for performing a chemiluminescent reaction comprising the aforesaid reagent.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: July 14, 2020
    Assignee: BIO-HELIX CO., LTD.
    Inventors: Cheng-Yen Lee, Chia-Wen Lien
  • Methods and compounds for treating paramyxoviridae virus infections
    Patent number: 10696679
    Abstract: Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 30, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dorothy Agnes Theodore